|14th October 2020||Bryan Giraudo||3,000||Open or private purchase||$10.01||$30,036.00|
|11th August 2020||Chaitan Phd Khosla||2,499||Open or private sale||$17.19||$42,952.06|
|11th August 2020||Chaitan Phd Khosla||2,499||Exercise of derivative||$1.89||$4,723.11|
|23rd June 2020||Bryan Giraudo||2,000||Open or private purchase||$12.96||$25,922.40|
|29th April 2020||Dinesh V Ph D Patel||2,000||Bona fide gift||$0.00|
|20th March 2020||Dinesh V Ph D Patel||10,000||Exercise of derivative||$1.89||$18,900.00|
|12th March 2020||Dinesh V Ph D Patel||18,344||Exercise of derivative||$1.16||$21,279.04|
|12th March 2020||Harold E Selick||12,000||Open or private purchase||$6.70||$80,400.00|
|14th February 2020||Bryan Giraudo||46,500||Grant/award etc.||$0.00|
|3rd December 2019||Dinesh V Ph D Patel||10,000||Open or private purchase||$5.55||$55,500.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm's initial lead product candidates are being developed for moderate-to-severe ulcerative colitis and Crohn's disease.